Opioid Overdose Clinical Trial
Official title:
A Phase I Single Dose, Open Label, Randomized, Three Period Crossover Pilot Study to Compare the Pharmacokinetics, Safety and Tolerability of MVP005 Intranasal Spray With Intranasal Administration of Naloxone Solution for Injection in Healthy Adult Subjects
This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie nasal spray (Test Product) and as a solution for injection (Comparator Product) administered intranasally using a mucosal atomization device (MAD).
Naloxone hydrochloride is currently only recommended and licensed for intravenous, intramuscular and subcutaneous administration. It has also been used by intranasal administration (off-label use) when the intravenous route is not suitable by administering the Solution for Injection using a mucosal atomization device (MAD). However, due to the volume of naloxone solution administered this way, some of it may be inadvertently swallowed and not absorbed into the nasal mucosa and the product requires administration by medically trained personnel. The study aims to investigate intranasal administration of naloxone using a more concentrated solution and a nasal delivery device. ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04372238 -
The Rhode Island Prescription and Illicit Drug Study
|
N/A | |
| Recruiting |
NCT03924505 -
Preventing Opioid Overdose Mortality in the United States
|
N/A | |
| Completed |
NCT05093309 -
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
|
N/A | |
| Completed |
NCT05219669 -
Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens
|
Phase 1 | |
| Completed |
NCT04317053 -
Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program
|
Phase 3 | |
| Recruiting |
NCT04815590 -
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
|
||
| Active, not recruiting |
NCT05096429 -
Preventing Overdose Using Information and Data From the Environment
|
N/A | |
| Suspended |
NCT05114460 -
Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal
|
Phase 2 | |
| Not yet recruiting |
NCT05876572 -
Blood Naloxone Levels Following Intradermal Injection in Humans
|
Phase 4 | |
| Completed |
NCT02662153 -
Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
|
||
| Active, not recruiting |
NCT05944133 -
Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
|
||
| Completed |
NCT05377255 -
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT05877118 -
Improving Availability of Intranasal Naloxone
|
N/A | |
| Recruiting |
NCT05072249 -
European Cohort Study of the Effectiveness of Take Home Naloxone
|
||
| Withdrawn |
NCT05808881 -
Clinical Outcomes From Nalmefene
|
Phase 4 | |
| Completed |
NCT05506267 -
Development of a Tracheal Sound Sensor
|
||
| Completed |
NCT02535494 -
Risks and Benefits of Naloxone Prescribing
|
N/A | |
| Completed |
NCT04713709 -
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder
|
Phase 1 | |
| Active, not recruiting |
NCT05008523 -
Opioids and Police Safety Study
|
N/A | |
| Completed |
NCT05363501 -
Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers
|
Phase 1 |